Clinical Trial Update: Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability evaluation of NNC0114-0006 at increasing doses in adults with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• NNC0114-0006

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Rheumatoid Arthritis | Phase 1 | Status: COMPLETED